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Abstract
Background: Angiogenesis, the growth of new blood vessels from the pre-existing vasculature is
associated with pathological processes, in particular tumour development, and is a target for the
development of new therapies. We have investigated the anti-angiogenic potential of two naturally
occurring stilbene glycosides (compounds 1 and 2) isolated from the medicinal plant Boswellia
papyriferai using large and smallvessel-derived endothelial cells. Compound 1 (trans-4',5'-dihydroxy-
3-methoxystilbene-5-O-{α-L-rhamnopyranosyl-(1→2)-[α-L-rhamnopyranosyl-(1→6)}-β-D-
glucopyranoside was the more hydrophilic and inhibited FGF-2-induced proliferation, wound
healing, invasion in Matrigel, tube formation and angiogenesis in large and small vessel-derived
endothelial cells and also in the chick chorioallantoic membrane assay. Using a binding assay we
were able to show compound 1 reduced binding of FGF-2 to fibroblast growth factor receptors-1
and -2. In all cases the concentration of compound 1 which caused 50% inhibition (IC50) was
determined. The effect of compound 1 on EGF and VEGF-induced proliferation was also
investigated.
Results: Compound 1 inhibited all stages of FGF-2 induced angiogenesis with IC50 values in the
range 5.8 ± 0.18 – 48.90 ± 0.40 μM but did not inhibit EGF or VEGF-induced angiogenesis. It also
inhibited FGF-2 binding to FGF receptor-1 and -2 with IC50 values of 5.37 ± 1.04 and 9.32 ± 0.082μM respectively and with concommotant down-regulation of phosphorylated-ERK-1/-2 expression.
Compound 2 was an ineffective inhibitor of angiogenesis despite its structural homology to
compound 1.
Conclusion: Compound 1 inhibited FGF-2 induced angiogenesis by binding to its cognate
receptors and is an addition to the small number of natural product inhibitors of angiogenesis
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Angiogenesis, the formation of new blood vessels from
the pre-existing vasculature, is a closely regulated
sequence of events beginning with the degradation of the
basement membrane by activated endothelial cells (ECs).
These then migrate and proliferate, form endothelial
sprouts and develop capillary tubes and a new basement
membrane. The key events of angiogenesis therefore
involve EC proliferation, migration, tube formation and
differentiation into capillaries [1]. Angiogenesis is associ-
ated with normal physiological (wound healing, endome-
trial cycle and embryonic development) and pathological
processes (tumour growth, rheumatoid arthritis, diabetic
retinopathy, and brain and cardiac infarctions) [2-4].
Angiogenesis is regulated by a balance between endog-
enous, soluble pro-angiogenic factors (including vascular
endothelial cell growth factor (VEGF) [5], fibroblast
growth factor-2 (FGF-2) [6], epidermal growth factor
(EGF) and angiopoietins, and anti-angiogenic factors
(including transforming growth factor-β, endostatin and
thrombospondin) [7-9]. Growth factors exert their effect
through binding to their cognate receptor; for example the
kinase insert domain-containing receptor (VEGF) and Tie-
2 receptors (angiopoietins) [10]. FGFs exert their effect by
binding to high affinity FGF-receptors (FGF-R) on the cell
surface. In vitro, ECs express FGFR-1 and in some cases
FGFR-2 but not FGFR-3 or -4 [11].
Because de-regulated angiogenesis is associated with dis-
ease progression, especially tumour development, inhibi-
tion of neo-vessel growth has become a target in drug
development. Natural compounds from medicinal plants
display diverse pharmacological activities and have
advantages over synthetic drugs, such as smoother action,
better tolerance and fewer allergic reactions [12]. For
example anti-angiogenic plant derived natural products
such as genistein [13], isoliquitrin [14], ginsenoside[15]
and torilin [16] have potent effects on EC proliferation or
tube formation.
Stilbene glycosides are natural products isolated from the
medicinal plant Euphobia chiradenia and in preliminary
screening were shown to be PLA2 inhibitors, have anti-
inflammatory properties and inhibit wound healing
although the mechanism of action was not investigated
[17]. Based on these results we speculated that stilbene
glycosides may be anti-angiogenic and tested the efficacy
of two of these compounds, trans-4',5'-dihydroxy-3-
methoxystilbene-5-O-{α-L-rhamnopyranosyl-(1→2)- [α-
L-rhamnopyranosyl-(1→6)}-β-D-glucopyranoside (com-
pound 1) and trans-4',5'-dihydroxy-3-methoxystilbene-5-
O-[α-L-rhamnopyranosyl-(1→6)]-β-D-glucopyranoside
(compound 2) (Figure 1; see methods) against large and
small vessel-derived EC in a range of in vitro and in vivo
angiogenic assays.
Results
Toxicity
Compounds 1 and 2 had no significant cytotoxic effect on
bovine aortic endothelial cells (BAEC) and human dermal
microvascular endothelial cells (HDMEC) over the con-
centration range used whereas staurosporine (an inducer
of active caspase-3 and a positive control) showed signifi-
cant cytotoxicity. Representative data for BAEC are shown
in Figure 2.
The effect of compounds 1 and 2 on growth factor-induced 
proliferation
Compounds 1 and 2 at concentrations of 1.4–71.5 μM
had no significant effect on BAEC and HDMEC growth in
the absence of growth factors (Figure 3).
Over a range of concentrations compound 1 inhibited
FGF-2-induced BAEC and HDMEC proliferation in a dose
dependent manner with IC50 values of 48.90 ± 0.40 and
The structures of the stilbene glycosides used in the studyFigure 1
The structures of the stilbene glycosides used in the study. Compound 1 (R = -L-rhamnose) and 2 (R = H).
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pound 2 was a less effective inhibitor and inhibited
HDMEC (IC50 of 101.0 ± 0.50 μM; p < 0.05) but had no
activity against large vessel BAEC (Table 1). The com-
pounds had little effect on vascular endothelial growth
factor (VEGF) or epidermal growth factor (EGF) stimu-
lated proliferation (Figure 3).
The effect of compounds 1 and 2 on endothelial cell 
migration during wound healing
Two- and three-dimensional cell migration assays were
used to determine whether compounds 1 and 2 had an
effect on EC cell migration. In a wound healing model,
cell monolayers were wounded and exposed to com-
pounds 1 or 2 with and without FGF-2. FGF-2 at a final
concentration of 25 ng/ml induced significant migration
into the denuded area (p = 0.001) and this was inhibited
by compound 1 with an IC50 value of 41.80 ± 0.95 μM (p
< 0.05; Figure 4A). Compound 2 was ineffective. Repre-
sentative photomicrographs are shown (Figure 4B).
The chemotactic effect of compounds 1 and 2 was meas-
ured in the three-dimensional Boyden chamber assay.
BAEC and HDMEC stimulated by FGF-2 (25 ng/ml)
showed a significant increase in migration (p < 0.05 in
both cases). Compound 1 inhibited migration of both cell
types in a dose-dependent manner with IC50 values of
30.05 ± 0.85 and 21.50 ± 0.6 μM respectively (p < 0.05;
Figure 4C). Compound 2 was ineffective with IC50 values
in excess of 800 μM.
The effect of compounds 1 and 2 on endothelial tube 
formation
In the presence of FGF-2 (25 ng/ml) there was an increase
in BAEC and HDMEC differentiation into capillary-like
structures (approximately 4.0 fold; p = 0.007 in each case:
Figure 5A). This process was inhibited by compound 1 in
a dose dependent manner with IC50 values of 11.12 ± 0.28
and 5.8 ± 0.18 μM (p < 0.05 in both cases) for BAEC and
HDMEC respectively. Figure 5 shows representative
results for BAEC. Compound 2 had no inhibitory activity.
The effect of compounds 1 and 2 on the regression of
established tubular networks formed from BAEC was also
investigated. Compound 1 had an IC50 value of 40.0 ± 0.2
The effect of compounds 1 and 2 on BAEC viabilityFigure 2
The effect of compounds 1 and 2 on BAEC viability. 
The cytotoxic effect was determined using (A) The MTT 
assay; cells (7.5 × 103) were incubated with the test com-
pounds or with staurosporine (1.4 μM) an inducer of active 
caspase-3 and of apoptosis for 72 h and MTT added. The 
absorbance was read at 570 nm. (B) Active-caspase-3 apop-
tosis assay: cells (4.0 × 104/ml) were incubated with the test 
compounds or with staurosporine (1.0 μM, 24 h) and stained 
with anti-active caspase-3 as described below. Experiments 
were performed in triplicate. Representative immunofluores-
cence photomicrographs for BAEC were taken as described 
below. A group of apoptotic cells are highlighted in II.
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The effect of compound 1 on growth factor induced BAEC proliferationFigure 3
The effect of compound 1 on growth factor induced 
BAEC proliferation. Cells were seeded in a 6-well plate in 
the numbers shown and the effect of compound 1 on growth 
factor-induced proliferation (25–75 ng/ml) was determined 
as described below. Columns 1 seeded cells; 2 DMSO alone; 
3 growth factor alone; 4–7 compound 1 at concentrations of 
1.43, 14.3, 28.6 and 71.5 μM. Values which differ significantly 
(p < 0.05) from growth factor alone are indicated by *. 
Results are the mean of three experiments.
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BMC Cell Biology 2009, 10:30 http://www.biomedcentral.com/1471-2121/10/30and compound 2 of 37.42 ± 0.63 μM respectively (p <
0.05 in both cases; Figure 6 shows representative results).
The effect of compounds 1 and 2 on endothelial invasion 
in Matrigel
The effect of the test compounds on cell invasion was
investigated using a Transwell Boyden chamber system
coated with reconstituted growth factor-depleted
Matrigel. BAEC and HDMEC treated with FGF-2 showed a
3.2 and 3.0 fold increase in migration into a second layer
of Matrigel respectively (p = 0.002). This process was
inhibited by compound 1 with IC50 values of 11.12 ± 0.28
and 5.8 ± 0.18 μM (p < 0.05 in both cases; Figure 7A) and
compound 2 with IC50 values of 18.90 ± 0.50 and 32.46 ±
0.95 μM (p < 0.05) for BAEC and HDMEC respectively.
Representative photomicrographs for the effect of com-
pound 1 are shown (Figure 7B).
Binding studies with FGF-2 receptors
The anti-angiogenic effect of compounds 1 and 2 may
occur by either competing with FGF-2 for its receptors or
by altering receptor binding. If compound 1 and 2 were
added with FGF-2 to FGFR-1 or FGFR-2 no significant
inhibitory effect was observed. However, if the com-
pounds were pre-incubated with FGF-2 a significant
reduction of FGF-2 binding for compound 1 (IC50 = 9.32
± 0.729 μM for FGFR-1 and 5.37 ± 1.04 μM for FGFR-2)
was observed (Figure 8). Compound 2 had no inhibitory
effect and neither compounds affected binding to the
VEGF receptor (results not shown).
The inhibition of ERK1/2 phosphorylation by compounds 1 
and 2
FGF-2 induced cell proliferation, migration and differen-
tiation is mediated through receptor binding and associ-
ated intracellular signal pathways involving ERK1/2 [18].
FGF-2 addition caused a 50% increase in ERK1/2 phos-
phorylation compared to the control. This was inhibited
by compound 1 in a dose-dependent manner (Figure 9A
and 9B). Compound 2 was ineffective.
Inhibition of angiogenesis in the chick chorioallantoic 
membrane (CAM) assay
Since the in vitro assays described above suggest inhibition
of several steps of angiogenesis we next studied the inter-
action of compounds 1 and 2 with FGF-2 in an in vivo sys-
tem, the CAM assay. There was no evidence of
angiogenesis or inflammation with the control, methyl-
cellulose, used for the addition of the test compounds
(Figure 10i). After exposure to FGF-2 (25 ng) there was a
significant increase in the formation of new blood vessels
growing radially towards the stimulus (Figure 10ii) (m =
3, p < 0.001, n = 15). The determination of the degree of
angiogenesis (m) is described below in the materials and
methods section. After 6 days exposure to the test com-
pounds (10 μg in each case) there was a 100% reduction
in FGF-2-induced angiogenesis in the case of compound 1
(Figure 10v; m = 0, p < 0.0001, n = 8) and 90% reduction
with compound 2 (Figure 10vi; m = 1, p = 0.0186, n = 5)
with a notable inhibition in the formation of normal
CAM blood vessels. The test compounds alone were not
inflammatory or angiogenic (Figure 10iii and 10iv).
Hydrophobicity of 1 and 2
The hydrophobicity descriptor (log P; a measure of the rel-
ative hydrophobicity) for compounds 1 and 2 were -0.07
and 0.76 respectively indicating that compound 1 is
approximately an order of magnitude more water soluble
than 2 but both compounds are very water soluble.
Table 1: A summary of the anti-angiogenic properties of stilbene glycosides. 
Assay Compound 1 Compound 2
BAEC HDMEC BAEC HDMEC
Proliferation in 15% FBS NS NS NS NS
EGF-induced proliferation NS NS NS NS
VEGF-induced proliferation NS NS NS NS
FGF-2-induced proliferation 48.90 ± 0.40 42.0 ± 0.93 NS 101.0 ± 0.50
FGF-2-induced migration 41.8 ± 0.95 ND NS ND
FGF-2-induced chemotaxis 30.05 ± 0.85 21.50 ± 0.6 800.0 ± 2.78 953.1 ± 3.50
FGF-2-induced tube formation 18.20 ± 0.65 12.4 ± 0.85 NS NS
FGF-2 invasion in matrigel 11.12 ± 0.28 5.8 ± 0.18 18.90 ± 0.50 32.46 ± 0.95
Tubular regression 40.0 ± 0.2 ND 37.42 ± 0.63 ND
Effect on binding to FGFR-1 5.37 ± 1.04 NS
Effect on binding to FGFR-2 9.32 ± 0.082 NS
In vivo CAM assay 100% inhibition 90% inhibition
NS = Not significant, overall inhibition is less than 50% and therefore IC50 values cannot be calculated. ND = not determined
Figures are the IC50 values ± SD (μM) and are the mean of at least three determinations.Page 4 of 12
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Effect of stilbene glycosides on FGF-2 induced BAEC migrationFigure 4
Effect of stilbene glycosides on FGF-2 induced BAEC migration. (A) A cell monolayer was wounded as described 
below and recovery was assessed in the presence of increasing concentration of the test compounds. Results are shown for 
compound 1. Values significantly different from FGF-2 alone (p < 0.05) are shown by *. (B) Representative photomicrographs 
(original magnification × 20) show the effect of compound 1 on BAEC migration. DMSO was used as the control. (C) The 
effect compound 1 on FGF-2-induced cell migration in a three dimensional Boyden chamber assay. Cells were added to the 
upper chamber and the compound at a range of concentrations, with and without FGF-2 (25 ng/ml) added to the lower cham-
ber (see below for method). The total number of migrated cells to the lower chamber was counted as described below. Col-
umn 1, control. The results are the mean of three experiments and values significantly different from FGF-2 alone (p < 0.05) 
are shown by *.
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The effect of compound 1 on BAEC tube formation in Matrigel with and without FGF-2Figure 5
The effect of compound 1 on BAEC tube formation in Matrigel with and without FGF-2. (A) Compound 1 inhib-
ited FGF-2 (25 ng/ml) induced BAEC differentiation into capillary like structures: column1, control. In the absence of FGF-2 
there was no inhibitory effect on tube formation. Values significantly different from FGF-2 alone (p < 0.05) are shown by *. 
Results are the mean of three experiments (B) Representative photomicrographs (original magnification × 20) show tube for-
mation by BAEC. In the presence of FGF-2 a closed tubular network was evident (an example is shown in II) and this was abol-
ished by compound 1 (shown in IV). In the control (I0 and with compound 1 alone (III) there was no evidence of tube 
formation.
BMC Cell Biology 2009, 10:30 http://www.biomedcentral.com/1471-2121/10/30The effect of compounds 1 and 2 on EGF and VEGF-
induced angiogenesis
Compounds 1 or 2 had no significant inhibitory effect on
EGF or VEGF-induced BAEC- or HDMEC growth or differ-
entiation as measured in the angiogenesis assays
described above (Table 1).
Discussion and conclusion
We have demonstrated the ability of compound 1, a
plant-derived stilbene glycoside to inhibit multiple stages
of angiogenesis in in vivo and in vitro assays with IC50 val-
ues in the range of 5.8 ± 0.18 to 48.90 ± 0.40 μM. Com-
pound 1 was equally effective against small and large
vessel-derived ECs but compound 2 was largely ineffec-
tive. Compound 1 which contains an additional bulky L-
rhamnose residue and is approximately 10 times more
water soluble than compound 2 was the more effective
inhibitor. Since the compounds show approximately 90%
structural homology, activity appears to be inversely
related to hydrophobicity. We have shown using other
plant-derived natural products that increased polarity cor-
relates with effectiveness of growth factor inhibition. For
example, the ability of sesterterpenes to inhibit FGF-2-
induced angiogenesis [18] and cheiradone to inhibit
VEGF [19] increased with polarity.
Stilbene glycosides and their derivatives are naturally
occurring phytoalexins, widely distributed and with
diverse activities. For example resveratrol, a stilbene glu-
coside inhibited the differentiation of human umbilical
vein ECs into capillary-like structures at concentrations of
0.1–1 mM [20] and induced apoptosis in colon cancer
cells [21]. Angiogenesis is an invasive process that requires
degradation of the basement membrane, cell migration
and removal of obstructing matrix proteins to allow space
for the formation of the vessel lumen [22]. Matrix metal-
loproteinases (MMPs), in particular MMP-2 and -9 are the
principal mediators of these events [23]. Stilbene glyco-
sides are potent anti-oxidants with IC50 values in the μM
range [24] and may suppress MMP expression, and there-
fore angiogenesis by decreasing oxidative stress, a known
inducer of MMP-9. This may indirectly regulate angiogen-
esis [25]. However, we were able to show that the major
effect of compound 1 was in reducing FGF-2 induced ang-
iogenesis. In the absence of growth factors, stilbene glyco-
sides had little effect on EC proliferation and migration.
However, compound 1 bound to FGF-2 reducing its bind-
ing to its cognate receptors (FGFR-1 and -2) with IC50 val-
ues of 5.37 to 9.32 μM respectively. The effect was specific
with no inhibition of EGF or VEGF activity and com-
pound 1 did not bind in vitro to the VEGF receptor. Ang-
iogenesis is regulated by a balance between pro- and anti-
angiogenic regulators. If the pro-angiogenic stimulators
predominate ECs switch to an angiogenic phenotype. It
appears that stilbene glycosides regulate angiogenesis by
decreasing the activity of pro-angiogenic FGF-2. In addi-
tion compounds 1 and 2 showed activity in the in vivo
CAM assay. The suppression of FGF-2 induced vascular
networks was accomplished without inflammation or
embryo death. In vitro, compound 1 reduced the forma-
tion of vascular networks by BAECs and HUVECs on
Matrigel beds and caused regression of established net-
works. Compound 1 also reduced FGF-2 induced prolifer-
ation and migration of ECs. It is possible therefore, that
compound 1 may have a role in reducing excessive angio-
genesis.
Activation of signal transduction pathways follows bind-
ing of growth factors to receptor tyrosine kinases and in
the case of FGF-2 involves phosphorylation of ERK-1 and
-2, culminating in the activation of the transcription factor
c-jun and initiation of the early events of angiogenesis
[26]. We were able to show that compound 1 reduced lev-
els of phospho-ERK-1 and -2 in FGF-2 stimulated ECs in a
dose-response manner.
(A) The effect of compound 1 on the regression of estab-lished BAEC ubular networksFigure 6
(A) The effect of compound 1 on the regression of 
established BAEC tubular networks. Cells were treated 
with FGF-2 on matrigel until an established tubular network 
was visible. The test compounds were added in serum and 
after 24 h the number of closed areas was counted as 
described below. The results are the mean of three experi-
ments and values differing from the control are shown by *. 
(B) Representative photomicrographs of tubular structures 
shown for FGF-2 alone (control; panel I) and in the presence 
of compound 1 (panel II) show tubular regression in the 
presence of the test compound (original magnification × 20).Page 7 of 12
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The effect of compounds 1 (AI) and 2 (AII) on BAEC invasion into a Matrigel layer was studied using the chemoinvasion assay describ d belowFigure 7
The effect of compounds 1 (AI) and 2 (AII) on BAEC invasion into a Matrigel layer was studied using the chem-
oinvasion assay described below. Cells (1.7 × 104) were added to the Matrigel coated upper Boyden chamber and the 
compounds with or without FGF-2 added to the lower chamber. Cell invasion was measured after 24 h and assessed as 
described below. Values significantly different (p < 0.05) from FGF-2 alone are shown by *. Results are the mean of three 
experiments. (B) Representative photomicrographs are shown for the effect of compound 1 on BAEC (original magnification × 
20). Increased migration was seen with FGF-2 (25 ng/ml; panel II) and this was reduced in the presence of compound 1 (panel 
IV).
BMC Cell Biology 2009, 10:30 http://www.biomedcentral.com/1471-2121/10/30The few known natural product inhibitors of FGF-2
include two sesterterpenes, leucosesterterpene [18] and
torilin [16] and the aporphine alkaloid sinomenine [27].
Both torilin and sinomenine show potential as anti-
tumour agents, the latter is active against synovial carci-
noma [27]. Since compound 1 shows anti-angiogenic
activity with similar IC50 values to sinomenine there is a
possibility that it may have potential as an anti-tumour
agent.
Methods
Angiogenic inhibitors
Two stilbene glycosides, trans-4',5'-dihydroxy-3-meth-
oxystilbene-5-O-{α-L-rhamnopyranosyl-(1→2)- [α-L-
rhamnopyranosyl-(1→6)}-β-D-glucopyranoside (com-
pound 1) and trans-4',5'-dihydroxy-3-methoxystilbene-5-
O-[α-L-rhamnopyranosyl-(1→6)]-β-D-glucopyranoside
(compound 2) (Figure 1) were isolated from the medici-
nal plant Boswellia papyriferia. Their isolation and struc-
tural and chemical characterisation is described in detail
elsewhere [17].
Materials
Matrigel was obtained from Becton Dickinson, UK; FGF-2
and goat anti-active caspase-3 antibody from R&D Sys-
tems; VEGF165 from Apollo Cytokine Research, (Cam-
bridge, UK), EGF, VEGFR-1 and -2, FGFR-1 and -2, anti-
FGF-2 and anti-VEGF antibodies were obtained from
Santa Cruz Biotechnology (Heidelberg, GDR). ABTS per-
oxidase substrate kit (Vector, UK), Transwell chamber sys-
tem, culture plates and flasks (SLS, UK), anti-goat Alexa
flour 488 conjugated green fluorescence dye and other
chemical of commercial grade were purchased from
Sigma (Poole, UK).
Cell culture
Human dermal microvascular endothelial cells
(HDMECs) and the appropriate medium were purchased
from TCS Cellworks (Buckingham, UK) and were cultured
and maintained according to the supplier's instructions.
Bovine aortic endothelial cells (BAECs) were isolated and
characterised as described previously [28]. They were rou-
tinely cultured in Dulbecco's modified Eagles medium
(DMEM) in 5% CO2 at 37°C containing varying concen-
trations of foetal calf serum (FCS) as described above. All
cells were used between passages six to nine.
Cell proliferation studies
Cells were seeded in triplicate at a concentration of 6.0 ×
105/ml, in 2 ml of complete medium in 6-well plates.
After attachment (24 h), medium was replaced with
serum poor medium (SPM), containing 2.5% FCS in
which the cells grew at a significantly reduced rate.
The effect of increasing concentrations of compound 1 on FGF-2 binding to FGFR-1 and -2igure 8
The effect of increasing concentrations of compound 
1 on FGF-2 binding to FGFR-1 and -2. The soluble 
receptor was coated onto the wells of a 96-well plate and 
blocked with 1% BSA. The test compounds and growth fac-
tor were premixed for 2 h and added to the plate. After 2 h 
the plate was washed and incubated with antibodies to the 
growth factor, then peroxidase-conjugated IgG for 45 min. 
Peroxidase substrate was added and the absorbance read at 
405 nm (se below for detail).
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(A) Western blots of p-ERK-1 and -2 were performed on BAEC treated with compound 1 as described belowFigure 9
(A) Western blots of p-ERK-1 and -2 were performed 
on BAEC treated with compound 1 as described 
below. (B) The bar charts show relative protein expression 
compared to the control given an arbitrary value of 1.0. All 
experiments were performed at least twice and a represent-
ative example is shown. Lane 1 control, lane 2 FGF-2 (25 ng/
ml), lane 3 compound 1 (1.43 μM), lane 4 compound 1 (14.3 
μM) + FGF-2, lane 5 compound 1 (28.6 μM), lane 6 com-
pound 1 (28.6 μM) + FGF-2.
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VEGF (10 ng/ml) [29] and test compounds at different
concentration were added and cells incubated for a further
72 h. Control wells were treated with 5 μl DMSO. Concen-
tration ranges of test compounds and pre-incubation
times were based on pilot studies. After 72 h, cells were
washed in PBS, detached in 0.05%w/v trypsin in PBS, and
counted on a Coulter counter (Coulter Electronics,
Hialeah, FL) set to a threshold of 30 μm. Experiments
were performed in triplicate and repeated at least twice.
Chemotaxis assay
The effect of compounds 1 and 2 on cell migration was
examined in vitro using a modified Boyden chamber sys-
tem with 8.0 μm pore polycarbonate filter inserts (TSL,
UK). The filter was coated overnight with 0.1%w/v gela-
tine, and air-dried. Cells (1 × 105) were placed in the
upper part of the filter and test compounds at different
concentrations with and without growth factors were
added to the lower part in SPM. Cells were incubated at
37°C for 6 h and the filter removed and the upper side
containing non migrated cells wiped and rinsed. The fil-
ters were fixed (4% paraformaldehyde), and stained
(Geimsa) and cell migration in duplicate wells was deter-
mined by counting cell numbers on the lower surface.
Experiments were performed in triplicate and at least two
times.
Endothelial cell migration in wound healing
Cells (6 × 104/ml) were added to a Thermanox cover slip
in a 24-well plate in complete medium and incubated for
24–48 h. When confluent, the medium was replaced with
DMEM containing 0.1% FCS and incubated for a further
48 h. Cover slips were washed (PBS, × 3), wounded with
a sterile razor to produce a straight edged cut and washed
in PBS to remove dislodged cells. Cover slips were added
to a fresh 24-well plate in 0.1% FCS and incubated with
FGF-2 (or other growth factors) and a range of concentra-
tions of test compounds for 18 h. Under these conditions,
there was negligible proliferation but measurable migra-
tion. Slides were fixed in ethanol (100%), stained with
methylene blue and photographed. For each slide, 10
fields of view (2 mm × 1.45 mm) were counted at ran-
dom. Each experiment was performed in triplicate and at
least twice.
Cell differentiation and invasion assays in Matrigel
Cells (1.0 × 106/ml) were mixed with an equal volume of
Matrigel (Becton -Dickinson, Oxford, UK; prepared
according to the supplier's instructions) at 4°C. Aliquots
(80 μl) were added to the wells of a 48-well plate and
allowed to polymerise (1 h) then 500 μl of 15% FCS con-
taining FGF-2 (25 ng/ml; or other growth factors), with or
without test compounds was added. The cells were incu-
bated for 24 h at 37°C then fixed in 4% paraformalde-
hyde (5 min), washed in cold ethanol and the plate air
dried. Cells were stained with Geimsa (30 s), air dried and
photographed. Ten random fields were selected and the
number of closed tubes counted.
The procedure described above was repeated and wells
having a uniform network of tubes were used to assess
invasion into a second layer of Matrigel. Matrigel (100 μl),
with and without the test compounds was added to the
cells and allowed to polymerise (1 h at 37°C). FCS (15%)
was added and the cells incubated for 24–72 h when tube
growth into the upper layer was measured as described
above.
Tube regression under the influence of the test com-
pounds was also investigated. Cell suspensions were
mixed with Matrigel supplemented with FGF-2 (25 ng/
Compounds 1 and 2 inhibit in vivo angiogenesis in the CAM assay (see below for method)Figure 10
Compounds 1 and 2 inhibit in vivo angiogenesis in the 
CAM assay (see below for method). (I) methylcellulose 
alone showed no evidence of angiogenesis or inflammation, 
(II) FGF-2 induced a network of new blood vesselsradiating 
from the site of application (arrow), (III) and (IV) compounds 
1 and 2 (10 μg) alone again showed no inflammatory or ang-
iogenic response at the site of application. (V) and (VI) When 
compounds I and 2 (10 μg) were added together with FGF-2 
there was complete inhibition of blood vessel formation. 
Representative photomicrographs are shown and the arrow 
indicates the point of application of the test compounds. 
Original magnification × 40.Page 10 of 12
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to polymerise (1 h) and FCS (0.5 ml with FGF-2, (25 ng/
ml) added and cells incubated for 24 h. Wells which had
a uniform network of tubes (assessed with a Nikon
inverted microscope) were treated with medium (0.5 ml,
15% FCS) containing test compounds. Plates were incu-
bated for 24 h, fixed and stained as described above and
tube formation counted. All experiments were performed
in triplicate and at least two times.
Binding assay
Competition between growth factors, their cell surface
receptors and test compounds was assessed in an ELISA
assay as described by [30]. A 96-well plate was coated
overnight with 2 μg/ml of the soluble receptors (FGFR-1
or -2 and VEGFR-1 or -2) and blocked with 1% BSA in PBS
containing 0.05% Tween-20. The test compound and
FGF-2 or VEGF were pre-mixed for 2 h and added to the
plate and incubated for 2 h. The plate was washed (× 3
with PBS-Tween-20) and incubated with anti-FGF-2 IgG
(1:500 in PBS-Tween-20) or anti-VEGF IgG (!:250 in PBS-
Tween-20) for 45 min, washed and incubated with horse-
radish peroxidase conjugated goat anti-IgG (Santa Cruz,
1:1000) for a further 45 min. After washing (× 3), ABTS
peroxidase substrate was added and the absorbance read
at 405 nm. IC50 values were calculated from the data using
the EZ-Fit enzyme kinetic software (Perella Scientific Inc.,
Amherst, USA).
Western blotting
The method is described in detail elsewhere [18]. In brief,
cells were lysed in RIPA buffer, protein concentration
determined using the Biorad assay, and approximately 20
μg aliquots separated by 12% SDS-PAGE, electroblotted
onto nitrocellulose filters (Hoefer, San Francisco, Ca,
USA), blocked overnight with 1% BSA in TBS-Tween and
incubated for 4 h at RT with characterised antibodies to
phosphor-ERK1/2 (AutogenBioclear, mouse monoclonal,
1:1000). α-Actin (Sigma, UK; 1:1000) was used as a load-
ing control. Filters were washed in TBS-Tween and stained
with antibodies to peroxidase-conjugated secondary anti-
body. Proteins were detected with the ECL system (Amer-
sham, UK). Protein expression was estimated
spectrophotometrically from band intensity. Results are
semi-quantitative and given a numerical value compared
to the weakest observed band assigned an arbitrary value
of 1.0. All experiments were performed at least twice and
representative examples are shown.
Chick chorioallantoic assay
The angiogenic activity of test compounds was deter-
mined using the semi-quantitative chick chorioallantoic
assay (CAM) as described previously [31]. To expose the
CAM a window was created in the shells of 4 day-old
chicken eggs. On day 8, a 2 mm3 methycellulose pellet (5
μl of 1% sterile methylcellulose; 400 centipoise, Sigma
UK) containing no additions (control), the test com-
pound (10 μg) with and without FGF-2 (100 ng) were
applied to the membrane. The resultant angiogenesis
scored on day 14 as 0- negative; 0.5- change in vessel
architecture; 1- partial spokewheel (1/3 of circumference
exhibits directional angiogenesis); 2- spokewheel; 3 or
greater- strong and fully spokewheel. This approach ena-
bled calculation of an accumulated response in each
group. To photograph the membrane, 2 cm3 of a 50%
emulsion of aqueous paraffin oil containing 2% Tween-
80 was injected at the site of application and photo-
graphed using a Leitz dissecting microscope. Each experi-
ment was performed five times and statistical significance
was determined by the Mann-Whitney U test and the data
is expressed as a median value (m).
Toxicity
Stilbene glycoside toxicity was determined using the MTT
and active caspase-3 assays. BAECs or HDMECs (7.5 ×
103) were seeded in a 96 well plate and incubated for 4 h
to allow cell adhesion. The test compound or stau-
rosporine (1 μM), an inducer of active caspase-3 and
therefore of apoptosis was added to the wells. Control
cells were treated with PBS and the plate was incubated at
room temperature for 72 hours. MTT reagent (10 μl) was
added followed by incubation at room temperature for 2–
4 h. When a purple precipitate was visible, detergent rea-
gent (100 μl) was added to the plates and incubated at
room temperature for 2 h in the dark. Absorbance was
measured at 570 nm using a microplate reader.
In the apoptosis assay, HDMECs or BAEC (4 × 104/ml) in
complete medium were added to the chambers slide and
allowed to adhere for 24 h. The test compound (X μM) or
staurosporine (1 μM) were added to all wells except con-
trol (PBS) and incubated for 24 hours. Wells treated with
staurosporine were immediately washed (PBS) and fixed
(4% paraformaldehyde) when cell morphology became
round (2–4 h). After washing and fixing, cells were perme-
ablized (0.1% Triton X-100; 10 min), washed (× 5~5 min
each), air dried and blocked with 1% BSA in 1:50 TBS-
Tween for 1 h at room temperature. Cells were incubated
with goat anti-active caspase-3 (R&D system, UK; 1% BSA
in TBS-Tween) for 1 h. The plates were incubated with
anti-goat Alexa-Flour 488 conjugated green fluorescent
dye for 1.5 h at room temperature. Ten random homoge-
neous fields were viewed, and photographed.
Determination of the hydrophobicity of 1 and 2
The SdQSAR program [32] (Tripos, St Louis, Mo) was
used to determine the octanol-water partition coefficient
a measure of hydrophobicity.Page 11 of 12
(page number not for citation purposes)
BMC Cell Biology 2009, 10:30 http://www.biomedcentral.com/1471-2121/10/30Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Statistical analysis
All data were expressed as mean ± SEM. Statistical analysis
was performed by one way analysis of variance and a
value of p < 0.05 was considered statistically significant.
Authors' contributions
SH carried out the angiogenic assays. JG, MS and NA par-
ticipated in the design of the study and JG prepared the
manuscript. MIC and HN isolated and characterised the
stilbene glycosides. DW performed the CAM assay. All
authors read and approved the manuscript.
Acknowledgements
We would like to thank M Hoult for assistance in the preparation of the 
manuscript.
References
1. Folkmann J: Fundamental concepts of the angiogenic process.
Curr Mol Med 2003, 3:643-651.
2. Avouac J, Uzan G, Kahan A, Boileau C, Allanore Y: Endothelial pro-
genitor cells and rheumatic disorders.  Joint Bone Spine 2008,
75:131-137.
3. Slevin M, Kumar P, Gaffney J, Kumar S, Krupinski J: Can angiogen-
esis be exploited to improve stroke outcome? Mechanisms
and therapeutic potential.  Clin Sci (Lond) 2006, 111:171-183.
4. Kumaran G, Clamp AR, Jayson GC: Angiogenesis as a therapeutic
target in cancer.  Clin Med 2008, 8:455-458.
5. Slevin M, Kumar P, Wang Q, Kumar S, Gaffney J, Grau-Olivares M,
Krupinski J: New VEGF antagonists as possible therpapeutic
agents in vascular disease.  Expert Opin Investig Drugs 2008,
17:1301-1314.
6. Cao Y, Cao R, Hedlund EM: Regulation of tumor angiogenesis
and metastasis by FGF and PDGF signalling pathways.  J Mol
Med 2008, 86:785-789.
7. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E,
Birkhead JR, Olsen BR, Folkmann J: Endostatin: an endogenous
inhibitor of angiogenesis and tumor growth.  Cell 2007,
88:277-285.
8. Roberts DD: Thrombospondins: from structure to theapeu-
tics.  Cell Mol Life Sci 2008, 65:669-671.
9. Nyberg P, Xie L, Kalluri R: Endogenous inhibitors of angiogen-
esis.  Cancer Res 2005, 65:3967-3979.
10. Takahashi H, Shibuya M: The vascular endothelial growth factor
VEGF/VEGF receptor system and its role under physiologi-
cal and pathological conditions.  Clin Sci (Lond) 2005,
109:227-224.
11. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M: Fibrob-
last growth factor/fibroblast growth factor receptor system
in angiogenesis.  Cytokine and Growth Factor Reviews 2005,
16:159-178.
12. Nagy JA, Dvorak AM, Dvorak HF: EGF-A(164/165) and PIGF:
roles in angiogenesis and arteriogenesis.  Trends in Cardiovasc
Med 2003, 13:169-175.
13. Fotsis J, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano
R, Schweigerer L: Genistein, a dietary-derived inhibitor of in
vitro angiogenesis.  Proc Natl Acad Sci (Wash) 1993, 90:2690-2694.
14. Kobayashi S, Miyamoto T, Kimura I, Kimura M: Inhibitory effect of
isoliquitrin, a compound in licorice root, on angiogenesis in
vivo and tube formation in vitro.  Biol Pharm Bull 1995,
18:1382-1386.
15. Sato K, Mochizuki M, Saiki I, Yoo YC, Samukawa K, Azuma I: Inhibi-
tion of tumor angiogenesis and metastasis by a saponin of
Panax ginseng, ginsenoside-Rb2.  Biol Pharm Bull 1994,
17:635-639.
16. Kim MS, Lee YM, Moon E-J, Kim SE, Lee JJ, Kim K-W: Anti-ang-
iogenic activity of torilin, a sesquiterpene comp;ound iso-
lated from Torilis Japonica.  Int J Cancer 2000, 87:269-275.
17. Atta-ur-Rahman , Naz H, Makhmoor T, Yasin A, Fatima N, Ngounou
FN, Kimbu SF, Sondengam BL, Choudhary MI: Bioactive constitu-
ents from Boswellia papyrifera.  J Nat Prod 2005, 68:189-193.
18. Hussain S, Slevin M, Matou S, Ahmed N, Choudhary M, Ranjit R, West
D, Gaffney J: Anti-angiogenic activity of sesterterpenes; natu-
ral product inhibitors of FGF-2 induced angiogenesis.  Angio-
genesis 2008, 11:245-256.
19. Hussain S, Slevin M, Mesaik M, Elosta M, Matou S, Ahmed N, West D,
Gaffney J: Cheiradone: a vascular endothelial cell growth fac-
tor antagonist.  BMC Cell Biol 2008, 9:7.
20. Kimura Y, Okuda H: Effects of naturally occurring stilbene glu-
cosides from medicinal plants and wine on tumour growth
and lung metastasis in Lewis lung carcinoma-bearing mice.  J
Pharm Pharmacol 2000, 52:1287-1295.
21. Hwang JT, Kwak DW, Lin SK, Kim HM, Kim YM, Park OJ: Reserva-
tol induces apoptosis via modulation of AMPK signalling.  Ann
N Y Acad Sci 2007, 1095:441-448.
22. Zhang YZ, Shen JF, Xu JY, Xiao JH, Wang JL: Inhibitory effects of
2,3,5,4'-tetrahydoxystilbene-2-O-beta-D-glucoside on exper-
imental inflammation and cyclooxegenase 2 activity.  J Asian
Nat Prod Res 2007, 9:355-363.
23. Ghajar CM, George SC, Putnam AJ: Matrix metalloproteinases
control of capillary morphogenesis.   Crit Rev Eukaryot Gene Expr
2008, 18:251-278.
24. van Hinsbergh VW, Koolwijk P: Endothelial sprouting and angio-
genesis: matrix metalloproteinases in the lead.  Cardiovasc Res
2008, 78:203-212.
25. Yu F, Kamada H, Niizuma K, Endo H, Chan PH: Induction of MMP-
9 and endothelial injury by oxidative stress after spinal cord
injury.  J Neurotrauma 2008, 25:184-195.
26. Slevin MA, Krupinski J, Slowik A, Rubio F, Szczudlik A, Gaffney J: Acti-
vation of MAP kinase (ERK-1/ERK-2), tyrosine kinase and
VEGF in the human brain following acutr ischaemic stroke.
Neuroreport 2000, 11:2759-2764.
27. Li XJ, Yue PY, Ha WY, Wong DY, Tim MM, Wang PX, Wong RN, Liu
L: Effect of sinomenine on gene expression of the Il-1 beta-
activated human synovial sarcoma.  Life Sci 2006, 79:665-673.
28. Duraisamy Y, Slevin M, Smith N, Bailey J, Zweit J, Smith C, Ahmed N:
Effect of glycation on basic fibroblast growth factor induced
angiogenesis and activation of associated signal transduction
pathways in vascular endothelial cells; possible relevance to
wound healing in diabetes.  Angiogenesis 2001, 4:277-288.
29. Slevin M, Kumar S, Gaffney J: Angiogenic oligosaccharides of
hyaluronan induce multiple signalling pathways affecting vas-
cular endothelial cell mitogenic and wound healing
responses.  J Biol Chem 2002, 277:41046-41059.
30. Ifat S, Tamer L, Lubinsky-Mink S, Kuhn J, Adir N, Chaterejee S,
Schomburg D, Ron D, Mink S, Noam A, Shivani C, Dietmar S, Dina R:
Identification of residues important for primary receptor
binding and specificity in fibroblast growth factor 7.  J Biol
Chem 2000, 275:34881-34886.
31. West DC, Thompson WD, Sells PG, Burbridge MF: Angiogenesis
assays using the chick chorioallantoic membrane.  In Methods
in molecular Medicine-angiogenesis: reviews and protocols Edited by: Mur-
ray JC. Humana Press; 2001:107-130. 
32. Daunes S, D'Silva C: QSAR study on the contribution of log P
and Es to the in vitro antiprotozoal activity of glutathione
derivatives.  J Med Chem 2001, 44:2976-2983.Page 12 of 12
(page number not for citation purposes)
